February 12th, 2020

A Joint Clinical Research Collaboration among Tokyo Medical andDental University (TMDU), ACT Genomics, and ACTmed Seeks toInvestigate the Cancer Genomic Landscape of Japanese Population

SummaryTokyo Medical and Dental University (TMDU), ACT Genomics, and ACTmed
launched a joint clinical research collaboration aimed to establish comprehensive
genomic profiles of highly prevalent cancers within the Japanese population.

TMDU Bioresource Research Center (BRC) provides tissue samples and clinicalinformation collected from 2,000 cancer patients, and ACT Genomics and ACTmed
are responsible for genomic mutation analysis regarding 440 cancer genes.

The obtained data will be utilized to identify potential biomarkers for prognosis andpredict treatment response.

Tokyo Medical and Dental University (TMDU), ACT Genomics (Taipei, Taiwan), andACTmed (Japan) launched a joint clinical research collaboration aimed to establish
comprehensive genomic profiles of highly prevalent cancers within the Japanese
population. This retrospective study utilizes next-generation sequencing (NGS)
technology to investigate biomarkers associated with solid tumors collected from 2,000
cancer patients in TMDU Biobank Project. The study is expected to lead to future
development of safer and more effective drugs as well as new methods for diagnosis.
The study will interrogate genomic alterations of 440 genes involved in cancer
development, treatment response, drug resistance, as well as the immune system using
ACT Genomics’ flagship cancer gene panel list, ACTOnco®+, to perform comprehensive
genomic analyses. TMDU Bioresource Research Center (BRC, Director, Dr. JohjiInazawa) provides formalin-fixed paraffin-embedded (FFPE) samples and clinicalinformation. A CAP-accredited laboratory in ACT Genomics and ACTmed (applying forCAP-accreditation) are responsible for sequencing and bioinformatics analysis. Genomicmutation patterns including mutation, copy number variation (CNV), microsatellite
instability (MSI), and tumor mutation burden (TMB) will be integrated withclinicopathological information. The obtained data will be utilized to identify potential
biomarkers for prognosis and predict treatment response.
TMDU Medical Hospital and Dental Hospital are large hospitals that more than
500,000 patients visit a year. TMDU BRC was established in 2013 across the university
to recruit and store biospecimens and clinical data from consented patients of TMDU
Hospitals. Comprehensive informed consent has been obtained from 6,500 patients, andover 15,000 high quality biospecimens, including genomic DNA from peripheral blood orsaliva, serum, fresh frozen tissue samples and FFPE tissue samples, have been stored
as of September 2019. The detailed clinical information of those bioresources on BRC
server is safely managed and regularly updated from the Electronic Medical RecordSystem. A sample search system has also been organized, and the samples areavailable for distribution for research purposes to both internal and external researcherswith appropriate approval from Institutional Review Board (IRB). This three-way
collaboration will accelerate not only local precision medicine services but also facilitate
multinational collaborations.
About ACT Genomics
ACT Genomics has been offering tumor profiling and clinical services using its
proprietarily designed cancer gene panels in Asia since 2014. The company has
implanted its AI-enabled bioinformatics pipeline translating complex sequencing data into
useful medical interpretations to guide cancer treatment and clinical trials. Integrated
genomic databases with Asian specific genome profiling can be used to build thefoundation for precision cancer medicine for the Asian population through this researchcollaboration.
About ACTmed
ACTmed is a joint venture company established by ACT Genomics and Canon
Medical Systems Corporation in 2018, providing clinical sequence services in Japan.
Technology introduction from ACT Genomics expedites the progress in Japan towards
the establishment of genomic profiling and precision medicine.

Correspondence to:Bioresource Research Center (BRC)
Tokyo Medical and Dental University (TMDU)
E-mail: biobank@ml.tmd.ac.jp
Web: http://www.tmd.ac.jp/brc/

Institute of Open Innovation
Tokyo Medical and Dental University (TMDU)

E-mail: openinnovation.tlo@tmd.ac.jp
Web: https://tmdu-oi.jp/

ACT Genomics Co. Ltd.
E-mail: service@actgenomics.com
Web: http://www.actgenomics.com/

ACTmed Co., Ltd.
E-mail: info@actmed.jp
Web: https://www.actmed.jp/